Review
The aim of this narrative review is to explore the relationship between high-rate breakthrough cancer pain, which strongly impacts health-related quality of life and tumour characteristics, in the face of novel approaches that should provide guidance for future clinical practice.
Original Research
In this real-life study, the authors aim to evaluate the prognostic role of variations in cancer antigen 15.3 (CA15.3) and carcinoembryonic antigen (CEA) levels in patients with HR+/HER2− breast cancer treated with CDK4/6 inhibitors. The goal of this investigation is to consider whether it would be possible to use these markers as a monitoring tool to diagnose earlier, faster and in a more practical way.
Review
This article is a systematic review of the evidence published over the last two decades, focusing on recent advances in the diagnostic
and therapeutic options of leptomeningeal carcinomatosis.
Case Report
Women with breast cancer are at a higher risk of developing vulvar and vaginal atrophy (VVA). Ospemifene is approved to treat VVA in postmenopausal women with a history of breast cancer after completion of all breast cancer (including adjuvant) treatments. This article examines the background characteristics and outcomes in two postmenopausal women with a history of breast cancer who were treated with ospemifene for VVA.
Review
A novel class of targeted therapy has been approved for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer. There are currently three approved agents, which are oral cyclin-dependent kinase 4/6 (CDK4/6) inhibitors. In this review, all available data is summarized, unanswered questions are highlighted, and pharmacological differences between each CDK4/6 inhibitor are discussed.
